非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究*

doi:10.3969/j.issn.1672-5069.2019.04.018

摘要/Abstract

摘要： 目的调查非酒精性脂肪性肝病（NAFLD）肥胖儿童血清25羟维生素D₃[血清25-（OH）D₃]和白介素-17（IL-17）水平变化。方法 2014年1月~2017年12月我院诊治的肥胖儿童62例,参照非酒精性脂肪性肝病诊疗指南标准诊断单纯性非酒精性脂肪肝（NAFL）36例,非酒精性脂肪性肝炎（NASH）26例,另选健康儿童30例,采用ELISA法检测血清25-（OH）D和IL-17水平。结果 NAFL儿童血清25-（OH）D₃水平为（15.2±2.1） ng/mL,NASH儿童为（9.6±1.3） ng/ml,均显著低于健康儿童的（26.3±2.3） ng/mL,而血清IL-17水平分别为（17.1±7.8）μg/L和（36.2±12.6） μg/L,均显著高于健康儿童的（1.4±0.5） μg/L,差异均有统计学意义（P<0.05）;中度脂肪变儿童血清ALT和AST水平分别为（54.1±15.4） U/L和（46.5±12.6） U/L,重度组儿童分别为（117.1±37.1） U/L和（78.5±31.0） U/L,均显著高于轻度组的（33.4±4.6） U/L和（30.5±2.9） U/L（P<0.05）;中度脂肪变儿童血清25-（OH）D₃水平为（10.2±1.4） ng/ml,重度组儿童为（8.4±1.1） ng/ml,显著低于轻度组的（15.8±2.0） ng/mL（P<0.05）,而血清IL-7水平分别为（22.2±6.3） μg/L和（39.6±9.2） μg/L,显著高于轻度脂肪变儿童的（13.5±3.5）μg/L,组间差异均有显著性统计学意义（P<0.05）。结论 NAFLD儿童血清25-（OH）D3水平降低,而血清IL-17水平升高,它们的变化可能与肝内脂肪变程度有关,动态监测这些变化,可能对了解病情和防治效果判断起指导作用。

关键词: 非酒精性脂肪性肝病, 25羟维生素D₃, 白细胞介素-17, 肥胖儿童

Abstract: Objective To investigate serum 25-（OH）D₃ and interleukin-17（IL-17） levels in obese children with nonalcoholic fatty liver disease（NAFLD）.Methods Sixty-two obese children were enrolled in this study between January 2014 and December 2017,and out of them,36 cases were diagnosed as nonalcoholic fatty liver （NAFL） and 26 were nonalcoholic steatohepatitis （NASH）. Thirty healthy children were selected as control. Serum IL-17 and 25-（OH）D₃ levels were assayed by ELISA.Results Serum 25-（OH）D₃ level in children with NAFL was（15.2±2.1） ng/mL,and in children with NASH was （9.6±1.3） ng/ml,both significantly lower than （26.3±2.3） ng/mL in healthy children,while serum IL-17 levels were（17.1±7.8） μg/L and （36.2±12.6） μg/L,both significantly higher than（1.4±0.5） μg/L in healthy children（P<0.05）;serum ALT and AST levels in children with moderate NAFLD were （54.1±15.4） U/L and （46.5±12.6） U/L,and were （117.1±37.1） U/L and （78.5±31.0） U/L in children with severe NAFLD,all significantly higher than （33.4±4.6） U/L and （30.5±2.9） U/L in kids with mild NAFLD（P<0.05）;serum 25-（OH）D₃ level in children with moderate NAFLD was（10.2±1.4） ng/ml and in children with severe NAFLD was（8.4±1.1） ng/ml,both significantly lower than （15.8±2.0） ng/ml in children with mild NAFLD（P<0.05）,while serum IL-7 levels were（22.2±6.3）μg/L and （39.6±9.2） μg/L,respectively,significantly higher than （13.5±3.5） μg/L in children with mild NAFLD （P<0.05）. Conclusion Serum 25-（OH）D₃ levels decrease and serum IL-17 levels increase in obese children with NAFLD,which might be new indicators for supervision of disease progress.

Key words: Nonalcoholic fatty liver disease, NAFLD. 25-（OH）D₃, IL-17, Obese children

张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.

Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.

参考文献

[1] 金沛桦,施军平. 非酒精性脂肪性肝病:一种多系统疾病. 实用肝脏病杂志,2017,20(3):257-259.
[2] 赵泽华,范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道. 实用肝脏病杂志,2017,20(1):21-24.
[3] Jiao N,Baker SS,Chapa-Rodriguez A,et al.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut,2017,152(5):S1068.
[4] Doycheva I,Cui J,Nguyen P,et al.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther,2016,43(1):83-95.
[5] Eduardo F,Francisco F,Gemma V,et al.Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm,2013,2013(3):136584.
[6] Chehimi M,Vidal H,Eljaafari A.Pathogenic role of IL-17-producing immune cells in obesity,and related inflammatory diseases. J Clin Med,2017,6(7):68.
[7] Ali KR,Kapur P,Jain A,et al.Effect of orlistat on periostin,adiponectin,inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Ther Clin Risk Manag,2017,13:139.
[8] Clemente-Postigo M,Munoz-Garach A,Serrano M,et al.Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetes. J Clin Endocrinol Metab,2015,100(4):591-595.
[9] Wu L,Ong S,Talor MV,et al.Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med,2014,211(7):1449-1464.
[10] Hatting M,Tacke F.From NAFLD to HCC:is IL-17 the crucial link Hepatology,2016,65(2):739.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南 (2018年版). 实用肝脏病杂志,2018,21(2):177-186.
[12] Altinbas A,Sowa J P,Hasenberg T,et al.The diagnosis and treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol,2015,61(3):159-169.
[13] 王存川,张艺超. 肥胖症与代谢疾病外科治疗的发展. 中华消化外科杂志,2015,14(7):524-527.
[14] Ogden CL,Carroll MD,Kit BK,et al.Prevalence of childhood and adult obesity in the United States,2011-2012.JAMA,2014,311(8):806.
[15] 王红清,付映旭,徐佩茹,等. 25羟维生素D水平与儿童肥胖关系的 Meta分析. 中华临床医师杂志(电子版),2015,9(10):125-128.
[16] 张红霞,原杰,贺业新,等. 太原社区非糖尿病人群血清维生素D与腹型肥胖的相关性. 中华临床营养杂志,2015,23(4):219-223.
[17] Ferro M,Terracciano D, Buonerba C,et al.The emerging role of obesity,diet and lipid metabolism in prostate cancer. Future Oncol,2016,34(2):285-293.
[18] Su DL,Lu ZM,Shen MN,et al.Roles of pro-and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol,2012,2012(4):347141.
[19] Dobritsa SV,Kuok IT,Nguyen H,et al.Development of a high-throughput cell-based assay for identification of IL-17 inhibitors. J Biomol Screen,2013,18(1):75-84.
[20] Carla H,Chackelevicius N,Sabrina LG,et al.Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol,2016,22(41):9096-9103.
[21] Fawaz L,Mrad MF,Kazan JM,et al. Comparative effect of 25(OH)D₃ and 1,25(OH)₂D₃ on Th17 cell differentiation. Clin Immunol,2016,166-167:59-71.
[22] Webster GF,Webster TG,Grimes LR.Laboratory tests in patients treated with isotretinoin:occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality. Dermatol Online J,2016,23(5):103.
[23] Drori A,Rotnemergolinkin D,Avni S,et al.Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin d-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift. Bmc Gastroenterol,2017,17(1):130.
[24] Hakkak R,Gauss C,Bell A,et al.Short-term soy protein isolate feeding prevents liver steatosis and reduces serum ALT and AST levels in obese female Zucker rats. Biomedicines,2018,6(2):74-78.
[25] Karpyak V,Biernacka J,Geske J,et al.Genome-wide association analyses reveal snp-by-consumption interaction effects on ALT And AST levels in alcohol dependent patients. Eur Neuropsychopharmacol,2017,27(5):S412.

非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*

Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[3]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[4]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[5]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.